Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)
AstraZeneca snips IL-12 candidate from pipeline as it sharpens I/O focus
Tipping its hand as part of its quarterly R&D update, AstraZeneca reported it has dropped two early-stage cancer drugs and a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
